Patents Expiring in October 2033
✉ Email this page to a colleague
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
On Target Labs | CYTALUX | pafolacianine sodium | SOLUTION;INTRAVENOUS | 214907-001 | Nov 29, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | |||
Sarfe Pharms | SOAANZ | torsemide | TABLET;ORAL | 213218-001 | Jun 14, 2021 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ||||
Sarfe Pharms | SOAANZ | torsemide | TABLET;ORAL | 213218-002 | Jun 14, 2021 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ||||
Kadmon Pharms Llc | REZUROCK | belumosudil mesylate | TABLET;ORAL | 214783-001 | Jul 16, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE | ||||
Kadmon Pharms Llc | REZUROCK | belumosudil mesylate | TABLET;ORAL | 214783-001 | Jul 16, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE | ||||
Kadmon Pharms Llc | REZUROCK | belumosudil mesylate | TABLET;ORAL | 214783-001 | Jul 16, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOLD DISEASE | ||||
Vifor Pharma | VELTASSA | patiromer sorbitex calcium | POWDER;ORAL | 205739-004 | Oct 2, 2023 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF HYPERKALEMIA | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |